Merck & Co., Inc.
Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada
Key metrics · each point sourced
Stated objectives
Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial
sourceEvaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007
sourceEvaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007
sourceSubmit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results
sourceInitiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC
sourceFull-year sales forecast
sourceFull-year EPS forecast
sourceImproving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies
sourceBecome the premier research-intensive biopharmaceutical company in the world
sourceDeliver innovative health solutions that advance the prevention and treatment of diseases in people and animals
source